Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive Disorder

NCT07644130 | Not Yet Recruiting

• 1 other identifier: R26017
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to expand access to Bergen Four-Day Treatment (B4DT) in Finland and to integrate it into psychiatric care pathways at Tampere University Hospital (TAYS). A Bergen team has been established within TAYS Psychiatry and has been trained in collaboration with the B4DT team from HUS and the Norwegian developers. The objective of this study is to enhance understanding of the model's adaptability to the Finnish healthcare system, evaluate healthcare professionals' attitudes toward the intervention, and assess treatment outcomes. The aim is to recruit approximately 35 patients for the study. Patients will be recruited from a minimum of three groups (15 patients) and up to a maximum of six groups (35 patients). The criteria for admission to B4DT and for participation in the study are identical. The treatment and the study may include patients receiving specialized psychiatric care at Tampere University Hospital who have been diagnosed with obsessive-compulsive disorder and who experience significant impairment due to their symptoms. In addition, personnel from TAYS Psychiatry who recommend and refer patients for B4DT will be recruited for the study. The estimated number of participating staff members is approximately 30.

Conditions

Obsessive Compulsive Disorder (OCD)

Keywords

Bergen; B4DT; intensive treatment; OCD

Outcome Measures

Primary Outcomes (5)

• Yale-Brown Obsessive-Compulsive Scale, Self-Report (Y-BOCS-SR)

  Changes in OCD symptoms will be assessed using the Yale-Brown Obsessive-Compulsive Scale, Self-Report (Y-BOCS-SR), a ten-item self-report measure with each item rated from 0 to 4. Total scores range from 0 to 40, with higher scores indicating more severe symptoms.

  From pre-assessment to the end of follow-up approximately four to six months.

• Obsessive-Compulsive Inventory - Revised (OCI-R)

  In addition to the Y-BOCS, changes in OCD symptoms will be assessed using the Obsessive-Compulsive Inventory - Revised (OCI-R), which consists of 18 items, each rated from 0 to 4, with total scores ranging from 0 to 72 points. Higher scores indicate more severe symptoms.

  From pre-assessment to the end of follow-up approximately four to six months.

• Client Satisfaction Questionnaire (CSQ-8)

  Patients will be asked about their satisfaction with the treatment using the Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 consists of eight items, each rated on a scale from 1 to 4, with total scores ranging from 8 to 32. Higher scores indicate greater satisfaction with the treatment.

  From pre-assessment to the end of follow-up approximately four to six months.

• Credibility and Expectancy Questionnaire (CEQ)

  Patients' treatment expectations will be assessed using the Credibility and Expectancy Questionnaire (CEQ). The CEQ includes six items: four rated from 1 to 9 and two from 0% to 100%, with higher scores indicating greater expectations and confidence in the treatment.

  approximately four months

• Self-report for healthcare professionals (AIM, IAM, FIM)

  The acceptability, appropriateness, and feasibility of the treatment will be assessed among healthcare professionals using a combination of three subscales: the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). The AIM, IAM, and FIM each consist of four items rated on a five-point scale. Accordingly, the total score for each scale ranges from 4 to 20 points. The total 12-item score ranges from 12 to 60, with higher scores indicating greater overall treatment acceptability.

  approximately four months

Secondary Outcomes (5)

• Patient Health Questionnaire (PHQ-9)

  From pre-assessment to the end of follow-up approximately four to six months.

• Generalized Anxiety Disorder Scale (GAD-7)

  From pre-assessment to the end of follow-up approximately four to six months.

• Work and Social Adjustment Scale (WSAS)

  From pre-assessment to the end of follow-up approximately four to six months

• Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

  From pre-assessment to the end of follow-up approximately four to six months.

• EuroQol 5-Dimension Questionnaire (EQ-5D)

  From pre-assessment to the end of follow-up approximately four to six months.

Study Arms (1)

Bergen Four-Day Treatment

EXPERIMENTAL

Other: Bergen Four-Day Treatment (B4DT)

Interventions

Bergen Four-Day Treatment (B4DT) OTHER

The intervention starts with a pre-assessment, during which patients' motivation, expectations, and willingness to engage in exposure practice are assessed. After the pre-assessment, patients participate in a four-day intensive treatment period based on exposure and response prevention. The intensive phase is an individualized intervention delivered within a group framework. This phase is followed by a three-month period of independent practice, with a couple of appointments with the therapist. Changes in patients' symptoms, daily functioning, and well-being are assessed. In addition, healthcare professionals' attitudes toward the intervention will be examined.

Bergen Four-Day Treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• diagnosed with obsessive-compulsive disorder
• willingness to participate in exposure-based treatment

You may not qualify if:

• intellectual disability
• autism spectrum disorder that precludes engagement in psychotherapeutic work
• a psychotic disorder with current psychotic symptoms
• underweight or very rapid weight loss affecting cognition
• severe suicidality
• substance dependence
• benzodiazepine medication (use of Z-drugs as sleep medication is permitted)
• In addition, ongoing psychotherapy may prevent participating in the B4DT.

Sponsors & Collaborators

• Tampere University Hospital: lead
• Tampere University: collaborator

Study Sites (1)

Tampere University Hospital

Tampere, Finland

Location

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Anxiety Disorders; Mental Disorders

Study Officials

• Aino Mattila

  Tampere University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Aino Mattila

CONTACT

+358503439168; aino.mattila@pirha.fi

Petra Sainio

CONTACT

+358444811252; petra.sainio@pirha.fi

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 25, 2026
• First Posted: June 12, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: June 12, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

FI (1)